Interpretation of Cerebral Oxygenation Changes in the Preterm Infant

Aisling A. Garvey [1,2], **Elisabeth M. W. Kooi** [1,3], **Aisling Smith** [1] and **Eugene M. Dempsey** [1,2,*]

[1] Department of Paediatrics and Child Health, Neonatal Intensive Care Unit, University College Cork, T12 YE02 Cork, Ireland; aisling.garvey@ucc.ie (A.A.G.); e.kooi@umcg.nl (E.M.W.K.); smithai@tcd.ie (A.S.)

[2] INFANT, Irish Centre for Fetal and Neonatal Translational research, University College Cork, T12 YE02 Cork, Ireland

[3] Division of Neonatology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands

[*] Correspondence: g.dempsey@ucc.ie; Tel.: +353-21-420-5040

Abstract: Near-infrared spectroscopy (NIRS) allows for continuous, non-invasive monitoring of end-organ tissue oxygenation. The use of NIRS, cerebral NIRS (cNIRS) in particular, in neonatal care has increased significantly over the last few years. This dynamic monitoring technique provides real-time information on the cerebral and haemodynamic status of the neonate and has the potential to serve as an important adjunct to patient care with some centres routinely utilising cNIRS to aid decision-making at the bedside. cNIRS values may be influenced by many variables, including cardiac, respiratory and metabolic parameters, and therefore it is essential to understand the pathophysiology behind alterations in cNIRS values. Correct interpretation is required to direct appropriate patient-specific interventions. This article aims to assist clinicians in deciphering cNIRS values by providing an overview of potential causes of fluctuations in cNIRS values, illustrated by common clinical scenarios, with particular emphasis on the preterm infant.

Keywords: near-infrared spectroscopy; NIRS; cerebral oxygenation; end-organ tissue oxygenation; neonate; preterm; individualised patient care

1. Introduction

Although introduced into clinical care almost 40 years ago, it is only in the last decade that near-infrared spectroscopy (NIRS) has grown in popularity in the Neonatal Unit (NNU) [1]. NIRS provides a continuous, non-invasive measurement of end-organ tissue oxygenation (rSO_2) and its ease of application and its potential usefulness has contributed to its increasing use, especially in the very preterm infant. Cerebral NIRS (cNIRS) provides a potential window into the cerebral and haemodynamic status of the neonate. The merits of NIRS monitoring have been discussed previously [2] and NIRS monitoring either alone, or in conjunction with other modalities, potentially has an important role to play in care of the newborn. Some centres now routinely use cNIRS to assist in decision-making at the bedside, especially in the care of the preterm infant.

Unlike pulse oximetry which measures arterial oxygen saturation, NIRS measures tissue oxygen saturation, which consists of a combination of arterial, venous, and capillary blood. While NIRS monitoring provides relative regional saturations and reference guidelines have been suggested [3,4], studies to date are heterogeneous in their study population and outcomes [5] and values have also been shown to vary with gestational age (6). There are a number of different devices used with a variety of algorithms incorporated, which may account for some of the variability that exists [6–9]. In addition, the type of sensor used can produce differences of up to 14% in values [6] and reapplication of the same probe in the same region can result in differences of up to 6% [8].

As clinicians, we are becoming increasingly aware of the importance of interpreting physiological data in the context of each individual infant, instead of a "one size fits all" approach, in order to provide optimum and appropriate individualised care. As a result, the challenge facing many clinicians lies in the interpretation of this relatively new bedside device. The trend of the values and signal itself are rich in information [10,11] but unlike peripheral oxygen saturation levels (SpO$_2$), cerebral tissue oxygen saturation is influenced by many potential variables, including cardiac (blood pressure and cardiac output), respiratory (partial pressure of carbon dioxide and oxygen in arterial blood), and metabolic (glycaemia) parameters. Correct interpretation of the cerebral oxygenation values/trends in light of such variables is essential if appropriate interventions are to be implemented, and changes in cerebral NIRS values should prompt a clinical evaluation of the infant to determine the underlying cause.

To gain more insight in the balance between arterial oxygen delivery to the brain and the brain's oxygen uptake, fractional tissue oxygen extraction (FTOE) has been utilised [12]. In newborn piglets this parameter appeared to correlate well with fractional oxygen extraction (FOE), as measured from blood oxygen content in arterial and venous blood samples. FTOE is calculated by dividing the difference between SpO$_2$ and rSO$_2$ divided by SpO$_2$ ((SpO$_2$–rSO$_2$)/SpO$_2$). This way, FTOE represents the fraction of the delivered oxygen that has been extracted by the tissue measured [12]. In reality, this also partly compensates for low arterial oxygen levels, as is often the case in preterm infants with lung disease, or in infants with congenital heart defects [13]. In these situations, FTOE may be a better parameter for brain perfusion (assuming a relative constant brain metabolism rate) than rSO$_2$, and potentially a better measure for the assessment of autoregulation when combined with blood pressure [14]. Figures 1 and 2 provide a schematic overview of potential influencing factors of NIRS values.


Figure 1. Causes of low cerebral oxygen saturation.

Figure 2. Causes of high cerebral oxygen saturation.

In this article, we concentrate solely on cerebral oxygen saturation values and suggest an approach to the interpretation of cNIRS at the bedside and provide examples of commonly encountered scenarios in the neonatal unit, with particular emphasis on the preterm infant in the first 72 h of life.

2. Hypotension

For over four decades, the question of low blood pressure and the need for use of inotropes has largely remained unanswered. Much of this uncertainty results from a lack of good quality evidence from large randomised controlled trials [15,16]. The association between hypotension and brain injury or poor neurodevelopmental outcome remains controversial [17–20]. Recently, focus has shifted towards incorporating the use of surrogate markers of end organ perfusion as a means to determine when treatment should be instigated. cNIRS as a surrogate of cerebral blood flow (assuming a stable cerebral oxygen consumption) has gained momentum and has also been utilised to assess inotrope use in preterm infants and their effect on cerebral perfusion and blood flow [21–23]. Also, when combined with blood pressure, as a surrogate for cerebral perfusion pressure it has the potential to provide a dynamic, continuous measurement of cerebral autoregulation [24].

Cerebral autoregulation is the mechanism by which cerebral blood flow remains constant despite fluctuations in cerebral perfusion pressure. Preterm infants are at an increased risk of impaired autoregulation, primarily due to the immaturity of smooth muscle cells of their cerebral arteries [25,26]. As mentioned, cNIRS can be used as an assessment of cerebral blood flow, and when combined with blood pressure as a surrogate for cerebral perfusion pressure, the cerebrovascular capacity in an infant can be evaluated. Uncertainty remains, however, regarding the interpretation of these values and the optimum algorithm to validly assess cerebrovascular autoregulation [24]. Accurate identification of periods of impaired autoregulation and cerebral compromise may provide opportunities for appropriate treatment to be initiated and continuously evaluated [27].

Below we illustrate the advantage of cNIRS when assessing the potential need for intervention in periods of low blood pressure. The figures provided are recorded using a Moberg CNS device (Moberg, PA, USA) and an INVOS 5100 (Somanetics, Troy, MI, USA) NIRS monitor with a neonatal probe. Figure 3 illustrates fluctuations in the infant's mean arterial blood pressure, with associated periods of low blood pressure, but the cerebral rSO_2 values remain stable and mean blood pressure spontaneously increases with time. The stable cNIRS trend during this period of low blood pressure may be a useful adjunct in decision-making about interventions, such as whether inotropes should be commenced or not.


Figure 3. Cerebral rSO_2 remains stable despite changes in blood pressure. This figure reflects the case of neonate born at 24 + 5 weeks gestation. Birth weight (BW) 660 g, day of life (DOL) 1.

In Figure 4 however, the periods of low blood pressure are associated with periods of simultaneous changes in cerebral oxygenation. This would suggest that cerebral autoregulation is not maintained and this infant may benefit from methods to stabilize the mean arterial blood pressure, although the cerebral oxygen saturation appears to be within adequate ranges.

Low cNIRS values can also provide invaluable information in assessing systemic circulation. A low cerebral rSO_2 value associated with signs of poor systemic perfusion such as a prolonged capillary refill time (CRT), and increased lactate or poor urine output would probably necessitate treatment to improve cardiac output [28,29] and tissue perfusion rather than an observational approach to the management. However, there is limited evidence from clinical studies to support such an approach.

Figure 4. Decreases in cerebral rSO_2 in association with decreases in blood pressure. This figure reflects the case of a neonate born at 27 + 6 weeks gestation. BW 770 g, DOL 1.

3. Patent Ductus Arteriosus: Significant or Not?

Patent ductus arteriosus (PDA) is the most common cardiovascular finding in preterm infants [30]. Although PDA is associated with significant pathologies, including necrotising enterocolitis (NEC), chronic lung disease, and intraventricular haemorrhage (IVH), causality remains debatable and the optimal management of PDA remains controversial [31]. Numerous studies have sought to provide guidance on what constitutes a haemodynamically "significant" PDA (hsPDA) and how to effectively identify which PDAs require medical/surgical closure [32–34]. Although many studies utilise chronic lung disease and ventilator dependence as primary outcomes, Lemmers et al. have demonstrated significantly lower cerebral rSO_2 values in infants with hsPDAs. In addition, these values normalised to values of infants in the control group following medical closure of the PDA [35–37]. This finding was even more pronounced in infants who were born small for gestational age (SGA) [38]. However, other studies report stable cNIRS values despite showing differences in mean arterial blood pressure (MABP) and abdominal rSO_2 values. It is recognised that with preservation of cerebral autoregulation, perfusion may be maintained in the face of a hsPDA [39–43].

An additional potential role of cNIRS is the assessment of cerebral perfusion during medical and surgical therapy directed at hsPDA closure. Ibuprofen has been the first-line medical treatment of PDA for over a decade. Prior to its introduction into routine clinical practice, Patel et al. conducted a randomised controlled trial comparing the effects of indomethacin and ibuprofen on cerebral haemodynamics. Indomethacin resulted in a significant decrease in cerebral blood flow and oxygen delivery after administration, whereas ibuprofen had no negative effects on cerebral haemodynamics [44]. A 2018 study reported that paracetamol administration did not affect cerebral haemodynamics as measured by NIRS. This evidence is useful in supporting the safety profile of paracetamol, which is increasingly prescribed following failure of PDA closure with ibuprofen [45].

The effect of surgical PDA ligation on cerebral oxygenation remains controversial. Huning et al. utilised cNIRS to report that there is no change in cerebral oxygenation during PDA ligation [46]. Contrary to this, studies have demonstrated a reduction in cNIRS values during and immediately after surgical PDA ligation [47–49]. Whether this is as a result of impaired blood flow or increased tissue oxygen utilisation during surgery is unclear, with studies reporting conflicting results.

Another consideration is that infants who undergo surgical PDA ligation tend to be of greater postnatal age and may have already failed medical/conservative management, which may have an impact on their baseline pre-surgery rSO_2 values and subsequent outcomes [50].

Studies are now attempting to link cNIRS findings to subsequent neurological outcome. Verhagen et al. have demonstrated a correlation between cNIRS values in the first two weeks of life and neurodevelopmental outcome at 2–3 years [5]. Further to this, Lemmers et al. have noted a relationship between longstanding low cerebral oxygenation values on cNIRS in premature infants requiring surgical ligation for hsPDA and decreased cerebellar volume on MRI imaging at term equivalent age. They postulate that low cerebral oxygenation secondary to hsPDA and systemic steal may cause reduced brain volume and myelination, with subsequent consequences on neurodevelopmental outcomes [50].

There are many physiological variables that influence the haemodynamic significance of a PDA including the oxygen carrying capacity of the blood, fluid and respiratory status, shunt severity, and autoregulatory capacity of the infant. Additionally, echocardiographic indices may not correlate directly with impaired cerebral oxygenation [39,41]. Therefore a thorough evaluation of the entire physiological status of the infant is required to determine the haemodynamic significance of a PDA. cNIRS measurements may prove a useful adjunct to the clinical, biochemical, and echocardiographic assessment of shunt significance and whether PDA closure should be pursued medically or surgically for an individual patient. The impact of post ligation syndrome and its management has not been evaluated with cNIRS.

4. Peripheral Arterial Oxygen Saturation

Until recently, pulse oximetry was the sole measure of effective provision of supplemental oxygen to meet metabolic demands. Studies have demonstrated a higher survival rate in infants <28 weeks gestation who were randomised to a SpO_2 target of 91–95% compared to those in the target SpO_2 group of 85–89% [51,52]. Clinical trials have also demonstrated an increased risk of morbidity in preterm infants with higher peripheral oxygen saturation targets, specifically an increased risk of chronic lung disease and retinopathy of prematurity (ROP) [51–56]. However, SpO_2 alone does not provide clarity on specific end organ perfusion and NIRS may be utilised to assess real-time end organ/cerebral oxygenation status. Baerts et al. demonstrated significantly higher cerebral rSO_2 values in preterm infants who were administered increased fractionated inspired O_2 (FiO_2) during an episode of desaturation, and cerebral rSO_2 remained high for several minutes afterwards [57]. They speculate that this is may be the result of an adaptation phenomenon of post hypoxic reperfusion in a cohort of infants with limited cerebral autoregulation. Figures 5–7 demonstrate fluctuations in cerebral rSO_2 values associated with alterations in peripheral SpO_2 values. Low cerebral rSO_2 values are resolved by improving pulmonary oxygen uptake, by either increasing the amount of supplementary oxygen administered or increasing the mean airway pressure. Following oxygen supplementation for an episode of desaturation the rSO_2 levels remain high, consistent with the above mentioned findings of Bearts et al. Increasing FiO_2 was the most common intervention identified in the recent SafeBoosC intervention trial, which reported a significant reduction in the burden of cerebral hypoxia in the experimental group with cNIRS monitoring [3]. The opposite is true with cerebral hyperoxia in which high levels of supplementary oxygen administered can result in undesired elevated cerebral rSO_2 levels, but there was no excess cerebral hyperoxia identified in the SafeBoosC trial. Isolated bradycardias have a lower impact on cerebral saturations than isolated desaturations or combined desaturation with bradycardia [58,59]. SGA infants appear to have higher cerebral rSO_2 values along with higher haemocrit levels [60]. This is possibly related to chronic in-utero hypoxia and a redistribution of blood flow in-utero [61,62]. Studies have shown that if foetal Dopplers show evidence of brain sparing in relation to the cerebral blood flow in the foetal circulation, this effect persists in the first 72 h of life, with a relatively greater cerebral blood flow compared to renal blood flow [61].

Figure 5. Decrease in cerebral rSO_2 associated with decrease in peripheral SpO_2 due to desaturations. The subsequent overshoot is likely due to the increased FiO_2. This figure reflects the case of a neonate born at 25 + 2 weeks gestation. BW 530 g, DOL 3.


Figure 6. Cerebral hyperoxia following an episode of desaturation treated with increased FiO_2. This figure reflects the case of a neonate born at 25 + 2 weeks gestation. BW 530 g, DOL 3.


Figure 7. Cerebral rSO_2 and peripheral SpO_2 are decreased by reducing administered FiO_2. This figure reflects the case of a neonate born at 25 + 2 weeks gestation. BW 530 g, DOL 1.

5. Carbon Dioxide: Hypocarbia versus Hypercarbia

Carbon dioxide is an important regulator of cerebral blood flow. Hypocapnia, particularly levels lower than 30mmHg, can negatively affect cerebral blood flow as a result of cerebral vasoconstriction [63]. This in turn leads to a reduction in oxygen delivery and can be identified by a low cerebral rSO_2 level [64–67]. Many studies document that low $PaCO_2$ levels are an important risk factor for white matter injury and subsequent development of cerebral palsy [63]. This is of particular relevance for ventilated infants where overventilation may result in hypocapnia. Low cerebral rSO_2 may be a visual marker to prompt assessment of ventilator settings and $PaCO_2$ levels. Figure 8 demonstrates a downward trend in cerebral rSO_2 with associated low $PaCO_2$ levels due to overventilation.


Figure 8. Elevated cerebral rSO_2 values associated with increased CO_2 levels which reduce following a decrease in CO_2 levels. This figure reflects the case of a neonate born at 25 + 2 weeks gestation. BW 830 g, DOL 1.

Conversely, the opposite is true of elevated $PaCO_2$ levels. Cerebral vasodilation may lead to increased cerebral blood flow with increased oxygen delivery and cerebral hyperperfusion. Hyperoxia as a result of increased $PaCO_2$ levels has also been associated with decreased brain activity as measured with electroencephalography (EEG) [68]. Cerebrovascular autoregulation is also challenged during hypercarbia [69–71]. Figure 9 illustrates increased cerebral rSO_2 levels in association with increasing CO_2 levels.

Figure 9. Initially low cerebral rSO_2 and end-tidal CO_2 ($EtCO_2$) levels which increase with increasing CO_2. This figure reflects the case of a neonate born at 23 + 6 weeks gestation. BW 530 g, DOL 2.

6. Anaemia: Anaemia versus Polycythaemia

Optimal cerebral oxygenation relies on appropriate oxygen delivery to the brain. Infants with anaemia have been shown to have lower cerebral rSO_2 values and higher fractional tissue oxygen extraction (FTOE) than infants with normal haemoglobin levels [72]. These values normalise following blood transfusion [64,73–76]. Infants with a low cerebral rSO_2 level and low haemoglobin level may benefit from a red cell transfusion to improve the oxygen-carrying capacity of the blood [77].

Interestingly, polycythaemia also results in impaired cerebral haemodynamics, specifically a lower cerebral blood flow velocity [78–80]. Partial exchange transfusions result in increased cerebral oxygenation levels likely secondary to improved cerebral blood flow [81].

7. Blood Glucose Level: Hypoglycaemia

Low birth weight infants are at a significantly higher risk of hypoglycaemia than their term counterparts; however, hypoglycaemia can be difficult to identify as most preterm infants are rarely symptomatic [82,83]. Hypoglycaemia is an independent risk factor for poor neurodevelopmental outcome [84,85], and thus clinicians must have a high index of suspicion and actively monitor for hypoglycaemia. cNIRS may have a role to play in hypoglycaemia monitoring in the future. Studies have shown that glycaemia affects cerebral oxygenation, particularly in the first days of life [86,87]. Low blood glucose level (BGL) is associated with increased cerebral blood flow and increased cerebral rSO_2 levels [88]. cNIRS may be a useful indicator of low blood glucose values and its subsequent management.

8. Discussion

This overview highlights the various causes for fluctuations in cerebral oxygenation in preterm infants, or especially low or high absolute values, and suggests a novel individualized approach to the preterm infant. It will require a new way of thinking, where multiple parameters are given due consideration in order to establish a composite assessment of an individual infant's current physiological status. Instead of one solution for an abnormal value, such as increasing FiO_2 when SpO_2 is low, one now must give careful consideration to all the potential causes for the value observed. Once the cause has been determined, a dynamic and patient specific management plan may be initiated. This multi-step and individualized way of approaching a problem may potentially reduce the infant's

burden of hypoxia/hyperoxia and the number of unnecessary interventions during the first days of life, and ultimately improve short term outcomes.

The question that must be answered before implementing such an approach is whether there is any true and relevant benefit for the patient. Does it really help to incorporate cerebral NIRS measurement in daily clinical neonatal care? The SafeBoosC trial was the first attempt at evaluating this important question. In this multicentre study, 166 preterm infants were randomly assigned to having visible cerebral NIRS measurements in combination with a pathophysiologically-oriented, evidence-based treatment guideline [89] which aimed to maintain cerebral saturation between 55 and 85%, or to the non-visible NIRS measurement and standard care. This treatment guideline contained the same items discussed in this review, for which the level of evidence varies between high quality evidence, i.e., with regards to blood transfusion for anaemia, and low-level evidence with regards to decreasing minute ventilation for pCO_2 reduction. The cut-off values were experience-based, and the INVOS device with the adult sensor was used [90] in this particular trial. A fluctuation from baseline cNIRS measurements, as we have proposed as a prompt to assess for causation and consideration of therapeutic intervention, was not part of the original trial. Following completion of this phase 2 trial, it was clear that it is feasible to reduce the burden of cerebral hypoxia, whereas the burden of hyperoxia was not reduced in the treatment arm. Increasing FiO_2, which is arguably the easiest intervention to increase a low cerebral rSO_2 value, was the most common intervention used (72.1%). Other interventions included altering ventilator settings in 13.7% and commencing an inotrope/vasopressor in 5.1%. A PDA was treated as a response to low cerebral saturations in 0.4% of cases. The causes for high cerebral oxygenation are less amenable to intervention and bar lowering the FiO_2, it is difficult to influence high rSO_2 values other than ensuring that the $PaCO_2$ value is stable.

Although cerebral hypoxia was reduced in this study, only a limited effect on the short term neurological outcomes was demonstrated. EEG and blood-derived markers for brain injury were not different between the groups [3]. Also, cranial ultrasound and brain MRI findings were not significantly different between intervention and control groups [91]. Interestingly, analysing the results as a function of burden of hypoxia, regardless of allocation to intervention or control group, the authors found more severe IVH, lower EEG burst rates and death in the infants in the fourth quartile of the burden of hypoxia, compared with the first to third quartiles. This effect was not seen for blood biomarkers [92]. We await the long-term outcome data from this group.

The fact that no short-term neurological differences were found between the experimental and control groups may potentially be due to a non-individualised approach to abnormal values; the exact and specific cause of the cerebral hypoxia may not have been targeted in each case. A 'one size fits all' approach of increasing FiO_2 for all low cerebral oxygen saturation values may not result in improved outcomes as the patient may have required an alternative intervention. Improved focus on eliminating other causes for reduced oxygen supply to the brain, such as hypocarbia, might prove effective in maintaining an adequate cerebral blood flow and accompanying oxygen saturation. Although not identified in the SafeBoosC trial, ubiquitous use of increased FiO_2 might even lead to unintended hyperoxia [57].

9. Conclusions

The patterns described in this review are examples of alterations in cerebral oxygenation related to differing clinical scenarios. It is hoped that these visual descriptions will assist in pattern recognition at the bedside, and will provide additional information to the clinician to guide more individualised interventions. The ultimate usefulness of cNIRS will need to be evaluated in a larger clinical trial. A larger phase 3 SafeBoosC trial is being planned which aims to enroll 1500 preterm infants to examine if cerebral NIRS can reduce the risk of death or severe brain injury at 36 weeks of gestation [93] This study aims to assess if monitoring and treating episodes of cerebral hypoxia and hyperoxia, results in improved outcomes for preterm infants. In the meantime, cNIRS is currently providing many valuable insights into the cerebral haemodynamics and effects of therapeutic interventions in

this very vulnerable population. This tool requires further study in order to fully ascertain its role in active neonatal management and ability to prognosticate neurodevelopmental outcome. It is hoped that the patterns described in this review will assist in identification of potential causes of altered cerebral oxygen saturation, thus providing the clinician with additional information to make a more informed management choice.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sood, B.G.; McLaughlin, K.; Cortez, J. Near-infrared spectroscopy: Applications in neonates. *Semin. Fetal Neonatal Med.* **2015**, *20*, 164–172. [CrossRef] [PubMed]
2. Garvey, A.A.; Dempsey, E.M. Applications of near infrared spectroscopy in the neonate. *Curr. Opin. Pediatr.* **2018**, *30*, 209–215. [CrossRef] [PubMed]
3. Plomgaard, A.M.; van Oeveren, W.; Petersen, T.H.; Alderliesten, T.; Austin, T.; van Bel, F.; Benders, M.; Claris, O.; Dempsey, E.; Franz, A.; et al. The SafeBoosC II randomized trial: Treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. *Pediatr. Res.* **2016**, *79*, 528–535. [CrossRef] [PubMed]
4. Van Bel, F.; Lemmers, P.; Naulaers, G. Monitoring neonatal regional cerebral oxygen saturation in clinical practice: Value and pitfalls. *Neonatology* **2008**, *94*, 237–244. [CrossRef] [PubMed]
5. Verhagen, E.A.; Van Braeckel, K.N.; van derVeere, C.N.; Groen, H.; Dijk, P.H.; Hulzebos, C.V.; Bos, A.F. Cerebral oxygenation is associated with neurodevelopmental outcome of preterm children at age 2 to 3 years. *Dev. Med. Child. Neurol.* **2015**, *57*, 449–455. [CrossRef] [PubMed]
6. Alderliesten, T.; Dix, L.; Baerts, W.; Caicedo, A.; van Huffel, S.; Naulaers, G.; Groenendaal, F.; van Bel, F.; Lemmers, P. Reference values of regional cerebral oxygen saturation during the first 3 days of life in preterm neonates. *Pediatr. Res.* **2016**, *79*, 55–64. [CrossRef] [PubMed]
7. Kleiser, S.; Nasseri, N.; Andresen, B.; Greisen, G.; Wolf, M. Comparison of tissue oximeters on a liquid phantom with adjustable optical properties. *Biomed. Opt. Express* **2016**, *7*, 2973–2992. [CrossRef] [PubMed]
8. Greisen, G. Is near-infrared spectroscopy living up to its promises? *Semin. Fetal Neonatal Med.* **2006**, *11*, 498–502. [CrossRef] [PubMed]
9. Dix, L.M.; van Bel, F.; Baerts, W.; Lemmers, P.M. Comparing near-infrared spectroscopy devices and their sensors for monitoring regional cerebral oxygen saturation in the neonate. *Pediatr. Res.* **2013**, *74*, 557–563. [CrossRef] [PubMed]
10. Wong, F.Y.; Barfield, C.P.; Campbell, L.; Brodecky, V.A.; Walker, A.M. Validation of cerebral venous oxygenation measured using near-infrared spectroscopy and partial jugular venous occlusion in the newborn lamb. *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* **2008**, *28*, 74–80. [CrossRef] [PubMed]
11. O'Toole, J.M.; Kenosi, M.; Finn, D.; Boylan, G.B.; Dempsey, E.M. Features of cerebral oxygenation detects brain injury in premature infants. In Proceedings of the 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Orlando, FL, USA, 16–20 August 2016; pp. 3614–3617.
12. Naulaers, G.; Meyns, B.; Miserez, M.; Leunens, V.; Van Huffel, S.; Casaer, P.; Weindling, M.; Devlieger, H. Use of tissue oxygenation index and fractional tissue oxygen extraction as non-invasive parameters for cerebral oxygenation. A validation study in piglets. *Neonatology* **2007**, *92*, 120–126. [CrossRef] [PubMed]
13. Mebius, M.J.; van der Laan, M.E.; Verhagen, E.A.; Roofthooft, M.T.; Bos, A.F.; Kooi, E.M. Cerebral oxygen saturation during the first 72h after birth in infants diagnosed prenatally with congenital heart disease. *Early Hum. Dev.* **2016**, *103*, 199–203. [CrossRef] [PubMed]
14. Vesoulis, Z.A.; Liao, S.M.; Mathur, A.M. Gestational age-dependent relationship between cerebral oxygen extraction and blood pressure. *Pediatr. Res.* **2017**, *82*, 934–939. [CrossRef] [PubMed]

15. Giesinger, R.E.; McNamara, P.J. Hemodynamic instability in the critically ill neonate: An approach to cardiovascular support based on disease pathophysiology. *Semin. Perinatol.* **2016**, *40*, 174–188. [CrossRef] [PubMed]

16. Stranak, Z.; Semberova, J.; Barrington, K.; O'Donnell, C.; Marlow, N.; Naulaers, G.; Dempsey, E. HIP Consortium. International survey on diagnosis and management of hypotension in extremely preterm babies. *Eur. J. Pediatr.* **2014**, *173*, 793–798. [CrossRef] [PubMed]

17. Miall-Allen, V.M.; de Vries, L.S.; Whitelaw, A.G. Mean arterial blood pressure and neonatal cerebral lesions. *Arch. Dis. Child.* **1987**, *62*, 1068–1069. [CrossRef] [PubMed]

18. Bada, H.S.; Korones, S.B.; Perry, E.H.; Arheart, K.L.; Ray, J.D.; Pourcyrous, M.; Magill, H.L.; Runyan, W.; Somes, G.W.; Clark, F.C.; et al. Mean arterial blood pressure changes in premature infants and those at risk for intraventricular hemorrhage. *J. Pediatr.* **1990**, *117*, 607–614. [CrossRef]

19. Watkins, A.M.; West, C.R.; Cooke, R.W. Blood pressure and cerebral haemorrhage and ischaemia in very low birthweight infants. *Early Hum. Dev.* **1989**, *19*, 103–110. [CrossRef]

20. Dammann, O.; Allred, E.N.; Kuban, K.C.; Van Marter, L.J.; Pagano, M.; Sanocka, U.; Leviton, A. Systemic hypotension and white-matter damage in preterm infants. *Dev. Med. Child. Neurol.* **2002**, *44*, 82–90. [CrossRef] [PubMed]

21. Pellicer, A.; Valverde, E.; Elorza, M.D.; Madero, R.; Gayá, F.; Quero, J.; Cabanas, F. Cardiovascular support for low birth weight infants and cerebral hemodynamics: A. randomized, blinded, clinical trial. *Pediatrics* **2005**, *115*, 1501–1512. [CrossRef] [PubMed]

22. Bravo, M.C.; López-Ortego, P.; Sánchez, L.; Riera, J.; Madero, R.; Cabañas, F.; Pellicer, A. Randomized, Placebo-Controlled Trial of Dobutamine for Low Superior Vena Cava Flow in Infants. *J. Pediatr.* **2015**, *167*, 572–578. [CrossRef] [PubMed]

23. Valverde, E.; Pellicer, A.; Madero, R.; Elorza, D.; Quero, J.; Cabanas, F. Dopamine versus epinephrine for cardiovascular support in low birth weight infants: Analysis of systemic effects and neonatal clinical outcomes. *Pediatrics* **2006**, *117*, e1213–e1222. [CrossRef] [PubMed]

24. Kooi, E.M.; Verhagen, E.A.; Elting, J.W.; Czosnyka, M.; Austin, T.; Wong, F.Y.; Aries, M.J.H. Measuring cerebrovascular autoregulation in preterm infants using near-infrared spectroscopy: An overview of the literature. *Expert Rev. Neurother.* **2017**, *17*, 801–818. [CrossRef] [PubMed]

25. Haruda, F.D. The structure of blood vessels in the germinal matrix and the autoregulation of cerebral blood flow in premature infants. *Pediatrics* **2001**, *108*, 1050–1051. [CrossRef] [PubMed]

26. Wong, F.Y.; Leung, T.S.; Austin, T.; Wilkinson, M.; Meek, J.H.; Wyatt, J.S.; Walker, A.M. Impaired autoregulation in preterm infants identified by using spatially resolved spectroscopy. *Pediatrics* **2008**, *121*, e604–e611. [CrossRef] [PubMed]

27. Da Costa, C.S.; Greisen, G.; Austin, T. Is near-infrared spectroscopy clinically useful in the preterm infant? *Arch. Dis. Child. Fetal Neonatal Ed.* **2015**, *100*, F558–F561. [CrossRef] [PubMed]

28. Van der Laan, M.E.; Roofthooft, M.T.; Fries, M.W.; Schat, T.E.; Bos, A.F.; Berger, R.M.; Kooi, E.M. Multisite Tissue Oxygenation Monitoring Indicates Organ-Specific Flow Distribution and Oxygen Delivery Related to Low Cardiac Output in Preterm Infants with Clinical Sepsis. *Pediatr. Crit. Care Med.* **2016**, *17*, 764–771. [CrossRef] [PubMed]

29. Van der Laan, M.E.; Schat, T.E.; Olthuis, A.J.; Boezen, H.M.; Bos, A.F.; Kooi, E.M. The Association between Multisite Near-Infrared Spectroscopy and Routine Hemodynamic Measurements in Relation to Short-Term Outcome in Preterms with Clinical Sepsis. *Neonatology* **2015**, *108*, 297–304. [CrossRef] [PubMed]

30. Van Overmeire, B.; Chemtob, S. The pharmacologic closure of the patent ductus arteriosus. *Semin. Fetal Neonatal Med.* **2005**, *10*, 177–184. [CrossRef] [PubMed]

31. Evans, N. Preterm patent ductus arteriosus: A continuing conundrum for the neonatologist? *Semin. Fetal Neonatal Med.* **2015**, *20*, 272–277. [CrossRef] [PubMed]

32. Zonnenberg, I.; de Waal, K. The definition of a haemodynamic significant duct in randomized controlled trials: A systematic literature review. *Acta Paediatr.* **2012**, *101*, 247–251. [CrossRef] [PubMed]

33. McNamara, P.J.; Sehgal, A. Towards rational management of the patent ductus arteriosus: The need for disease staging. *Arch. Dis. Child. Fetal Neonatal Ed.* **2007**, *92*, F424–F427. [CrossRef] [PubMed]

34. Alagarsamy, S.; Chhabra, M.; Gudavalli, M.; Nadroo, A.M.; Sutija, V.G.; Yugrakh, D. Comparison of clinical criteria with echocardiographic findings in diagnosing PDA in preterm infants. *J. Perinat. Med.* **2005**, *33*, 161–164. [CrossRef] [PubMed]

35. Lemmers, P.M.; Toet, M.C.; van Bel, F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. *Pediatrics* **2008**, *121*, 142–147. [CrossRef] [PubMed]

36. Dix, L.; Molenschot, M.; Breur, J.; de Vries, W.; Vijlbrief, D.; Groenendaal, F.; van Bel, F.; Lemmers, P. Cerebral oxygenation and echocardiographic parameters in preterm neonates with a patent ductus arteriosus: An observational study. *Arch. Dis. Child. Fetal Neonatal Ed.* **2016**, *101*, F520–F526. [CrossRef] [PubMed]

37. Vanderhaegen, J.; De Smet, D.; Meyns, B.; Van De Velde, M.; Van Huffel, S.; Naulaers, G. Surgical closure of the patent ductus arteriosus and its effect on the cerebral tissue oxygenation. *Acta Paediatr.* **2008**, *97*, 1640–1644. [CrossRef] [PubMed]

38. Cohen, E.; Dix, L.; Baerts, W.; Alderliesten, T.; Lemmers, P.; van Bel, F. Reduction in Cerebral Oxygenation due to Patent Ductus Arteriosus Is Pronounced in Small-for-Gestational-Age Neonates. *Neonatology* **2017**, *111*, 126–132. [CrossRef] [PubMed]

39. Van der Laan, M.E.; Roofthooft, M.T.; Fries, M.W.; Berger, R.M.; Schat, T.E.; van Zoonen, A.G.; Tanis, J.C.; Bos, A.F.; Kooi, E.M. A Hemodynamically Significant Patent Ductus Arteriosus Does Not Affect Cerebral or Renal Tissue Oxygenation in Preterm Infants. *Neonatology* **2016**, *110*, 141–147. [CrossRef] [PubMed]

40. Petrova, A.; Bhatt, M.; Mehta, R. Regional tissue oxygenation in preterm born infants in association with echocardiographically significant patent ductus arteriosus. *J. Perinatol.* **2011**, *31*, 460–464. [CrossRef] [PubMed]

41. Schwarz, C.E.; Preusche, A.; Wolf, M.; Poets, C.F.; Franz, A.R. Prospective observational study on assessing the hemodynamic relevance of patent ductus arteriosus with frequency domain near-infrared spectroscopy. *BMC Pediatr.* **2018**, *18*, 66. [CrossRef] [PubMed]

42. Naulaers, G.; Delanghe, G.; Allegaert, K.; Debeer, A.; Cossey, V.; Vanhole, C.; Casaer, P.; Devlieger, H.; Van Overmeire, B. Ibuprofen and cerebral oxygenation and circulation. *Arch. Dis. Child. Fetal Neonatal Ed.* **2005**, *90*, F75–F76. [CrossRef] [PubMed]

43. Chock, V.Y.; Rose, L.A.; Mante, J.V.; Punn, R. Near-infrared spectroscopy for detection of a significant patent ductus arteriosus. *Pediatr. Res.* **2016**, *80*, 675–680. [CrossRef] [PubMed]

44. Patel, J.; Roberts, I.; Azzopardi, D.; Hamilton, P.; Edwards, A.D. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. *Pediatr. Res.* **2000**, *47*, 36–42. [CrossRef] [PubMed]

45. Dani, C.; Poggi, C.; Cianchi, I.; Corsini, I.; Vangi, V.; Pratesi, S. Effect on cerebral oxygenation of paracetamol for patent ductus arteriosus in preterm infants. *Eur. J. Pediatr.* **2018**, *177*, 533–539. [CrossRef] [PubMed]

46. Huning, B.M.; Asfour, B.; Konig, S.; Hess, N.; Roll, C. Cerebral blood volume changes during closure by surgery of patent ductus arteriosus. *Arch. Dis. Child. Fetal Neonatal Ed.* **2008**, *93*, F261–F264. [CrossRef] [PubMed]

47. Zaramella, P.; Freato, F.; Quaresima, V.; Ferrari, M.; Bartocci, M.; Rubino, M.; Falcon, E.; Chiandetti, L. Surgical closure of patent ductus arteriosus reduces the cerebral tissue oxygenation index in preterm infants: A near-infrared spectroscopy and Doppler study. *Pediatr. Int. Off. J. Jpn. Pediatr. Soc.* **2006**, *48*, 305–312. [CrossRef] [PubMed]

48. Lemmers, P.M.; Molenschot, M.C.; Evens, J.; Toet, M.C.; van Bel, F. Is cerebral oxygen supply compromised in preterm infants undergoing surgical closure for patent ductus arteriosus? *Arch. Dis. Child. Fetal Neonatal Ed.* **2010**, *95*, F429–F434. [CrossRef] [PubMed]

49. Chock, V.Y.; Ramamoorthy, C.; Van Meurs, K.P. Cerebral oxygenation during different treatment strategies for a patent ductus arteriosus. *Neonatology* **2011**, *100*, 233–240. [CrossRef] [PubMed]

50. Lemmers, P.M.; Benders, M.J.; D'Ascenzo, R.; Zethof, J.; Alderliesten, T.; Kersbergen, K.J.; Isgum, I.; de Vries, L.S.; Groenendaal, F.; van Bel, F. Patent Ductus Arteriosus and Brain Volume. *Pediatrics* **2016**, *137*, 20153090. [CrossRef] [PubMed]

51. Stenson, B.; Brocklehurst, P.; Tarnow-Mordi, W. Increased 36-Week Survival with High Oxygen Saturation Target in Extremely Preterm Infants. *N. Engl. J. Med.* **2011**, *364*, 1680–1682. [CrossRef] [PubMed]

52. Carlo, W.A.; Finer, N.N.; Walsh, M.C.; Rich, W.; Gantz, M.G.; Laptook, A.R.; Yoder, B.A.; Faix, R.G.; Das, A.; Poole, W.K.; et al. Target ranges of oxygen saturation in extremely preterm infants. *N. Engl. J. Med.* **2010**, *362*, 1959–1969. [PubMed]

53. Anderson, C.G.; Benitz, W.E.; Madan, A. Retinopathy of prematurity and pulse oximetry: A national survey of recent practices. *J. Perinatol.* **2004**, *24*, 164–168. [CrossRef] [PubMed]

54. STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. *Pediatrics* **2000**, *105*, 295–310.

55. Askie, L.M.; Henderson-Smart, D.J.; Irwig, L.; Simpson, J.M. Oxygen-saturation targets and outcomes in extremely preterm infants. *N. Engl. J. Med.* **2003**, *349*, 959–967. [CrossRef] [PubMed]

56. Schmidt, B.; Whyte, R.K.; Asztalos, E.V.; Moddemann, D.; Poets, C.; Rabi, Y.; Solimano, A.; Roberts, R.S. Effects of targeting higher vs. lower arterial oxygen saturations on death or disability in extremely preterm infants: A randomized clinical trial. *JAMA* **2013**, *309*, 2111–2120. [CrossRef] [PubMed]

57. Baerts, W.; Lemmers, P.M.; van Bel, F. Cerebral oxygenation and oxygen extraction in the preterm infant during desaturation: Effects of increasing FiO(2) to assist recovery. *Neonatology* **2011**, *99*, 65–72. [CrossRef] [PubMed]

58. Schmid, M.B.; Hopfner, R.J.; Lenhof, S.; Hummler, H.D.; Fuchs, H. Cerebral oxygenation during intermittent hypoxemia and bradycardia in preterm infants. *Neonatology* **2015**, *107*, 137–146. [CrossRef] [PubMed]

59. Petrova, A.; Mehta, R. Regional tissue oxygenation in association with duration of hypoxaemia and haemodynamic variability in preterm neonates. *Arch. Dis. Child. Fetal Neonatal Ed.* **2010**, *95*, F213–F219. [CrossRef] [PubMed]

60. Ishii, H.; Takami, T.; Fujioka, T.; Mizukaki, N.; Kondo, A.; Sunohara, D.; Hoshika, A.; Akutagawa, O.; Isaka, K. Comparison of changes in cerebral and systemic perfusion between appropriate- and small-for-gestational-age infants during the first three days after birth. *Brain Dev.* **2014**, *36*, 380–387. [CrossRef] [PubMed]

61. Tanis, J.C.; Boelen, M.R.; Schmitz, D.M.; Casarella, L.; van derLaan, M.E.; Bos, A.F.; Bilardo, C.M. Correlation between Doppler flow patterns in growth-restricted fetuses and neonatal circulation. *Ultrasound Obstet. Gynecol.* **2016**, *48*, 210–216. [CrossRef] [PubMed]

62. Cohen, E.; Baerts, W.; Alderliesten, T.; Derks, J.; Lemmers, P.; van Bel, F. Growth restriction and gender influence cerebral oxygenation in preterm neonates. *Arch. Dis. Child. Fetal Neonatal Ed.* **2016**, *101*, F156–F161. [CrossRef] [PubMed]

63. Greisen, G.; Vannucci, R.C. Is periventricular leucomalacia a result of hypoxic-ischaemic injury? Hypocapnia and the preterm brain. *Biol. Neonate* **2001**, *79*, 194–200. [PubMed]

64. Wardle, S.P.; Yoxall, C.W.; Weindling, A.M. Determinants of cerebral fractional oxygen extraction using near infrared spectroscopy in preterm neonates. *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* **2000**, *20*, 272–279. [CrossRef] [PubMed]

65. Pryds, O.; Greisen, G.; Skov, L.L.; Friis-Hansen, B. Carbon dioxide-related changes in cerebral blood volume and cerebral blood flow in mechanically ventilated preterm neonates: Comparison of near infrared spectrophotometry and 133Xenon clearance. *Pediatr. Res.* **1990**, *27*, 445–449. [CrossRef] [PubMed]

66. Dietz, V.; Wolf, M.; Keel, M.; v Siebenthal, K.; Baenziger, O.; Bucher, H. CO_2 reactivity of the cerebral hemoglobin concentration in healthy term newborns measured by near infrared spectrophotometry. *Biol. Neonate* **1999**, *75*, 85–90. [CrossRef] [PubMed]

67. Vanderhaegen, J.; Naulaers, G.; Vanhole, C.; De Smet, D.; Van Huffel, S.; Vanhaesebrouck, S.; Devlieger, H. The effect of changes in $tPCO_2$ on the fractional tissue oxygen extraction—As measured by near-infrared spectroscopy—In neonates during the first days of life. *Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc.* **2009**, *13*, 128–134. [CrossRef] [PubMed]

68. Dix, L.M.L.; Weeke, L.C.; de Vries, L.S.; Groenendaal, F.; Baerts, W.; van Bel, F.; Lemmers, P.M.A. Carbon Dioxide Fluctuations Are Associated with Changes in Cerebral Oxygenation and Electrical Activity in Infants Born Preterm. *J. Pediatr.* **2017**, *187*, 66–72. [CrossRef] [PubMed]

69. Pryds, A.; Tonnesen, J.; Pryds, O.; Knudsen, G.M.; Greisen, G. Cerebral pressure autoregulation and vasoreactivity in the newborn rat. *Pediatr. Res.* **2005**, *57*, 294–298. [CrossRef] [PubMed]

70. Kaiser, J.R.; Gauss, C.H.; Williams, D.K. The effects of hypercapnia on cerebral autoregulation in ventilated very low birth weight infants. *Pediatr. Res.* **2005**, *58*, 931–935. [CrossRef] [PubMed]

71. Kuik, S.J.; van der Laan, M.E.; Brouwer-Bergsma, M.T.; Hulscher, J.B.F.; Absalom, A.R.; Bos, A.F.; Kooi, E.M.W. Preterm infants undergoing laparotomy for necrotizing enterocolitis or spontaneous intestinal perforation display evidence of impaired cerebrovascular autoregulation. *Early Hum. Dev.* **2018**, *118*, 25–31. [CrossRef] [PubMed]

72. Whitehead, H.V.; Vesoulis, Z.A.; Maheshwari, A.; Rao, R.; Mathur, A.M. Anemia of prematurity and cerebral near-infrared spectroscopy: Should transfusion thresholds in preterm infants be revised? *J. Perinatol.* **2018**. [CrossRef] [PubMed]

73. Dani, C.; Pratesi, S.; Fontanelli, G.; Barp, J.; Bertini, G. Blood transfusions increase cerebral, splanchnic, and renal oxygenation in anemic preterm infants. *Transfusion* **2010**, *50*, 1220–1226. [CrossRef] [PubMed]

74. Dani, C.; Pezzati, M.; Martelli, E.; Prussi, C.; Bertini, G.; Rubaltelli, F.F. Effect of blood transfusions on cerebral haemodynamics in preterm infants. *Acta Paediatr.* **2002**, *91*, 938–941. [CrossRef] [PubMed]

75. Baenziger, O.; Stolkin, F.; Keel, M.; von Siebenthal, K.; Fauchere, J.C.; Das Kundu, S.; Dietz, V.; Bucher, H.U.; Wolf, M. The influence of the timing of cord clamping on postnatal cerebral oxygenation in preterm neonates: A randomized, controlled trial. *Pediatrics* **2007**, *119*, 455–459. [CrossRef] [PubMed]

76. van Hoften, J.C.; Verhagen, E.A.; Keating, P.; ter Horst, H.J.; Bos, A.F. Cerebral tissue oxygen saturation and extraction in preterm infants before and after blood transfusion. *Arch. Dis. Child. Fetal Neonatal Ed.* **2010**, *95*, F352–F358. [CrossRef] [PubMed]

77. Kalteren, W.S.; Kuik, S.J.; Van Braeckel, K.; Hulscher, J.B.F.; Bos, A.F.; Kooi, E.M.W.; van der Laan, M.E. Red Blood Cell Transfusions Affect Intestinal and Cerebral Oxygenation Differently in Preterm Infants with and without Subsequent Necrotizing Enterocolitis. *Am. J. Perinatol.* **2018**. [CrossRef]

78. Rosenkrantz, T.S.; Oh, W. Cerebral blood flow velocity in infants with polycythemia and hyperviscosity: Effects of partial exchange transfusion with Plasmanate. *J. Pediatr.* **1982**, *101*, 94–98. [CrossRef]

79. Maertzdorf, W.J.; Tangelder, G.J.; Slaaf, D.W.; Blanco, C.E. Effects of partial plasma exchange transfusion on cerebral blood flow velocity in polycythaemic preterm, term and small for date newborn infants. *Eur. J. Pediatr.* **1989**, *148*, 774–778. [CrossRef] [PubMed]

80. Bada, H.S.; Korones, S.B.; Kolni, H.W.; Fitch, C.W.; Ford, D.L.; Magill, H.L.; Anderson, G.D.; Wong, S.P. Partial plasma exchange transfusion improves cerebral hemodynamics in symptomatic neonatal polycythemia. *Am. J. Med. Sci.* **1986**, *291*, 157–163. [CrossRef] [PubMed]

81. Ergenekon, E.; Hirfanoglu, I.M.; Turan, O.; Beken, S.; Gucuyener, K.; Atalay, Y. Partial exchange transfusion results in increased cerebral oxygenation and faster peripheral microcirculation in newborns with polycythemia. *Acta Paediatr.* **2011**, *100*, 1432–1436. [CrossRef] [PubMed]

82. Koh, T.H.; Aynsley-Green, A.; Tarbit, M.; Eyre, J.A. Neural dysfunction during hypoglycaemia. *Arch. Dis. Child.* **1988**, *63*, 1353–1358. [CrossRef] [PubMed]

83. Sharma, A.; Davis, A.; Shekhawat, P.S. Hypoglycemia in the preterm neonate: Etiopathogenesis, diagnosis, management and long-term outcomes. *Transl.Pediatr.* **2017**, *6*, 335–348. [CrossRef] [PubMed]

84. Kerstjens, J.M.; Bocca-Tjeertes, I.F.; de Winter, A.F.; Reijneveld, S.A.; Bos, A.F. Neonatal morbidities and developmental delay in moderately preterm-born children. *Pediatrics* **2012**, *130*, e265–e272. [CrossRef] [PubMed]

85. Lucas, A.; Morley, R.; Cole, T.J. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. *BMJ* **1988**, *297*, 1304–1308. [CrossRef] [PubMed]

86. Vanderhaegen, J.; Vanhaesebrouck, S.; Vanhole, C.; Casaer, P.; Naulaers, G. The effect of glycaemia on the cerebral oxygenation in very low birthweight infants as measured by near-infrared spectroscopy. *Adv. Exp. Med. Biol.* **2010**, *662*, 461–466. [PubMed]

87. Skov, L.; Pryds, O. Capillary recruitment for preservation of cerebral glucose influx in hypoglycemic, preterm newborns: Evidence for a glucose sensor? *Pediatrics* **1992**, *90*, 193–195. [PubMed]

88. Pryds, O.; Christensen, N.J.; Friis-Hansen, B. Increased cerebral blood flow and plasma epinephrine in hypoglycemic, preterm neonates. *Pediatrics* **1990**, *85*, 172–176. [PubMed]

89. Pellicer, A.; Greisen, G.; Benders, M.; Claris, O.; Dempsey, E.; Fumagalli, M.; Gluud, C.; Hagmann, C.; Hellstrom-Westas, L.; Hyttel-Sorensen, S.; et al. The SafeBoosC phase II randomised clinical trial: A treatment guideline for targeted near-infrared-derived cerebral tissue oxygenation versus standard treatment in extremely preterm infants. *Neonatology* **2013**, *104*, 171–178. [CrossRef] [PubMed]

90. Hyttel-Sorensen, S.; Austin, T.; van Bel, F.; Benders, M.; Claris, O.; Dempsey, E.; Fumagalli, M.; Greisen, G.; Grevstad, B.; Hagmann, C.; et al. A phase II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline versus treatment as usual for extremely preterm infants during the first three days of life (SafeBoosC): Study protocol for a randomized controlled trial. *Trials* **2013**, *14*, 120. [CrossRef] [PubMed]

91. Plomgaard, A.M.; Hagmann, C.; Alderliesten, T.; Austin, T.; van Bel, F.; Claris, O.; Dempsey, E.; Franz, A.; Fumagalli, M.; Gluud, C.; et al. Brain injury in the international multicenter randomized SafeBoosC phase II feasibility trial: Cranial ultrasound and magnetic resonance imaging assessments. *Pediatr. Res.* **2016**, *79*, 466–472. [CrossRef] [PubMed]

92. Plomgaard, A.M.; Alderliesten, T.; Austin, T.; van Bel, F.; Benders, M.; Claris, O.; Dempsey, E.; Franz, A.; Fumagalli, M.; Gluud, C.; et al. Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial. *PLoS ONE* **2017**, *12*, e0173440. [CrossRef] [PubMed]

93. Rigshospitalet. Available online: https://www.rigshospitalet.dk/english/departments/juliane-marie-centre/department-of-neonatology/research/SafeBoosC-III/Sider/default.aspx (accessed on 8 July 2018).